Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease–a patent review (2016–present)
Introduction–AD, the most common form of dementia, has a multifactorial etiology, and the current therapy (AChEIs and memantine) is unable to interrupt its progress and fatal outcome. This is reflected in the research programs that are oriented toward the development of new therapeutics able to operate on multiple targets involved in the disease progression.